Transparent, Collaborative, Focused, Accountable

A team that has demonstrated success based on core principles of Integrity, Transparency, Rigorous Process, Constant Accountability and Celebrating Shared Success.

Michael Palazzi

Senior Managing Director

Michael brings 30 years of financial industry experience to Castle Hill.  Michael was head of NASDAQ Sales and Trading at CIBC World Markets (formally Oppenheimer and Co) for 17 years before moving to SG Cowen and Co. to Head up Global Sales trading and NASDAQ Trading. Following SG Cowen, Michael had leadership roles in derivatives trading at Pali Capital and Weeden and Co. Throughout his career, he has launched a number of entrepreneurial ventures and several start-up companies including Lions Path Capital and Cobalt Ventures where he served as founder, CFO and Risk Manager.

Michael holds the Series 7, 63 and 24 licenses.

Michael is based in the NY office. He is married with two children and is a resident of Sleepy Hollow, New York.

P: 212.764.6350

Andrew Saunders

Senior Managing Director

Andrew spearheads the consulting services and capital introduction program at Castle Hill Capital Partners.

Prior to founding Castle Hill, Andrew was most recently head of Capital Introduction at Lazard Capital Markets. He has also had leadership positions at Direct Access Partners and EFX Prime Services, a First New York initiative.

His first position on Wall Street was with Taylor Rafferty, a boutique cross-border investor relations firm. During his 7-year tenure, Andrew assisted senior management in implementing all aspects of their investor relations programs including corporate strategy development, IPO/Secondary roadshows, media relations and assisted senior management coordinate the investor relations activities for 12 ADR listings and IPOs on the NYSE and NASDAQ.

Andrew graduated from Haverford College in 1993 with a B.A. in Economics. He holds the Chartered Alternative Investment Analyst designation (CAIA) and is the Head of the New York Chapter with ~1,000 members. Prior to entering the financial services industry, Andrew spent four years in Malaysia and Indonesia as a teacher and entrepreneur.

Andrew holds the Series 7, 63 and 24 licenses.

Andrew is married with two children and lives in Brooklyn, NY and is currently training for his 9th marathon.

P: 212.764.9320

Brian Stutman

President and Chief Compliance Officer

Brian Stutman graduated cum laude from the University of Massachusetts, Amherst with Bachelor of Arts in 1989. He joined Wall Street after a 10 year entrepreneurial career and selling his last company, Employee Information Services, to a private equity firm.

Brian has 15+ years experience in trading, electronic trading and prime brokerage. Having started his career at Carlin Equities, Brian opened the West Palm Beach branch and was promoted to supervise all of Florida. Brian was the lead salesperson during his tenure at Carlin, staying with the firm for over 7 years until it was purchased by Royal Bank of Canada in 2006. At Royal Bank of Canada Brian held a key role in newly formed United States Prime desk, and was personally responsible for $5 billion in balances and generating over $12.5M in revenue for the bank. Brian then joined Lighthouse Financial Group as Managing Director and Co-Head of Prime Services. Brian was responsible for sales, marketing, operations, service, clearing and DMA relationships. Brian was most recently a Director at Lazard Capital Markets where he focused on prime brokerage and multi-product sales.

Brian holds Series 3, 7, 24, and 63 licenses.

Brian splits time between New York and South Florida where he raises 2 children.

P: 212.904.0280

Ken Smythe

Managing Director

Ken has over 15 years’ experience in capital raising, trading and private market transactions. Prior to joining Castle Hill, Ken was most recently President of Duet USA Asset Management, a $5.5 bln alternative investments firm where he spearheaded capital raising and the selection of portfolio management teams (2012-2017). He has also held leadership positions at Liongate Capital, Crystal Capital Partners and the New York Stock Exchange.

Ken graduated with an undergraduate degree from the University of Florida and has completed graduate level work in Securities Analysis at NYU as well as the Value Investing Program at Columbia University. Ken started his finance career in institutional sales at Neuberger Berman.

Ken holds the Series 7 and 3 licenses.

P: (646) 499-3002

Geoffrey Webster

Director of Operations and Chief Financial Officer

Geoffrey has been working in sales trading support for over 15 years with both bulge bracket and boutique Wall St. firms. While at Morgan Stanley, Geoffrey supported the Equity Program Trading desk, rising to manage the six-person group. At Goldman Sachs, Geoffrey was brought in to develop the middle office infrastructure for the Agency Program Trading Desk. Geoffrey also operated as an equity sales trader covering agency and principal trading strategies. In 2002 Geoffrey relocated to Florida where he spent 5 years as a proprietary trader with Carlin Equities/RBC Capital.

He spent the last 5 years heading the middle office, operations, and compliance for boutique prime brokerage groups.

Geoffrey currently holds his series 3, 4, 7, 24, 27 & 63 licenses.

He currently lives in West Palm Beach where he raises 3 children.

P: 212.784.6104

Tim McInerney

Managing Director

Mr. McInerney brings over 30 years of experience as a pharmaceutical executive and healthcare investment banker and analyst with positions in industry and a number of Wall Street firms. Following positions at Bristol, Myers Squibb, Bear Stearns, Shearson Lehman Brothers and Ladenburg Thalmann, Mr. McInerney oversaw the overall distribution of Paramount Capital’s private equity product and was directly responsible for over $1BB in capital raised for both startups and private placement investments.

In the early stage financings of Cougar Biotech (acquired by JNJ), Kite Pharma, Velcera (acquired by Perrigo) and Ziopharm Oncology, Mr. McInerney played a significant role.  He has served on numerous public and private boards including, Chairman of Insite Vision (acquired by Sun Pharmaceuticals) and Edgemont Pharmaceuticals (acquired by Alvogen, Inc.) and currently serves on the boards of Adgero BioPharmaceuticals, Emisphere Technologies and QSpex Technologies Inc. He also is a Co-Founding Investor and Board member of Corino Therapeutics and the sole managing member of Texas Oncology Investments, LLC.

Mr. McInerney received his BS in Pharmacy from St. John’s University in 1983 and also completed a post graduate residency in drug information systems at the New York University Medical Center.


Richard Fremont


Based in New York, Richard (Rick) began his career in the institutional brokerage industry in 1988. He has serviced all aspects of the institutional investment community, including registered investment advisors, hedge funds, mutual funds, public and private pension funds as well as the sell-side broker community. During his career, Rick has provided a wide array of services and technology on a consultative basis including a variety of fundamental, quantitative and technical research, data systems, technology, compliance, and infrastructure. He has worked in both domestic and international markets supporting a variety of investment strategies and vehicles to assist in organizing and assessing data and providing the appropriate tools to execute strategies. Most recently he has been evaluating and providing a range of big data products to the capital markets. Rick has worked for Lynch, Jones & Ryan (Citibank subsidiary), Hoenig & Co. (now ITG), Credit Agricole, Knight Capital Group and LaBranche (now Cowen & Co). He has spoken at industry conferences on a wide range of topics affecting the institutional marketplace.

Rick is a graduate of Seton Hall University and holds a B.A. in Political Science.  He also holds Series 7, 24 and 63 securities licenses.

P: (201) 988-7224

Copyright © Castle Hill Capital Partners, Inc. ("CHCP"), is a registered broker dealer with the Securities and Exchange Commission (SEC), and a member of the Financial Industry Regulatory Authority (FINRA). Disclaimer.